Autolus Therapeutics Reports 42.6-Month Median Response From FELIX Study, Showing Obe-Cel's Potential For Long-Term Remission In r/r B-ALL

+0.62% Post

AUTOLUS THERAPEUTICS LTD

AUTL

1.62

1.66

+0.62%

+2.47% Post

Median duration of response in FELIX study now 42.6 months after an additional 11 months of follow up
More than half of patients still in remission at 24 months
38% of ongoing responders did not receive any subsequent therapy by month 33
Results suggest a proportion of patients with r/r B-ALL may not need further therapy following treatment with obe-cel

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.